The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite
Research article published in Journal of cardiothoracic and vascular anesthesia (2020)
Abstract
Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.
Por qué esto importa para la hirudoterapia
Esta revisión examina el papel emergente de la bivalirudina como anticoagulante primario en cirugía cardíaca pediátrica, bypass cardiopulmonar, oxigenación por membrana extracorpórea, dispositivos de asistencia ventricular y cardiología intervencionista, ofreciendo un panorama de su farmacodinamia y métodos de monitorización. El resumen señala el creciente interés en la bivalirudina para sortear la resistencia a la heparina y la trombocitopenia inducida por heparina, aunque reconociendo que introduce desafíos adicionales. El resumen no menciona hirudina, sanguijuelas ni ninguna relación con la hirudoterapia, por lo que no existe una conexión defensible con la ASH sobre la base de esta fuente. Como revisión de la literatura existente, no genera datos clínicos nuevos.
Citación
The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite
Goswami A et al. · Journal of cardiothoracic and vascular anesthesia, 2020
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026